This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Seattle Genetics Announces ADCETRIS® Clinical Data To Be Reported In Multiple Presentations At ASCO Annual Meeting

Stocks in this article: SGEN

CD30 expression in non-lymphomatous malignancies (Abstract #3069)

In a screening study, assessment of CD30 expression was performed in patients who had a non-lymphoma malignancy and were relapsed or refractory to previous therapy, or had no alternative curative treatment option available. Patients with CD30 expression were eligible for a companion phase II clinical trial. Per the screening protocol, patients were considered to be CD30-positive and eligible for the companion clinical trial if at least 10 percent of malignant cells were positive by immunohistochemistry or at least 20 percent of malignant cells were positive by flow cytometry. At the time of data analysis, a total of 1,637 patients had been screened. Key findings include:

  • Thirty-eight patients (2 percent) and 17 different malignant diagnoses were CD30 positive per protocol.
  • The most common malignancies with CD30 expression were mesothelioma (5 of 18 patients; 28 percent), melanoma (6 of 64 patients; 9 percent), triple negative breast cancer (4 of 71 patients; 6 percent) and ovarian carcinoma (9 of 173 patients; 5 percent).
  • Assessment of CD30 expression under the screening protocol is ongoing with target enrollment of up to 3,000 patient tumor samples.
  • A phase II companion treatment protocol is ongoing to characterize the antitumor activity of ADCETRIS in patients with CD30-positive non-lymphoma malignancies and to correlate expression with activity.

Details of the poster presentation are as follows:

  • Monday, June 4; 8:00 a.m. to 12:00 p.m. CT
  • S Hall A2; poster board #16C
  • First author: Dr. Jeff P. Sharman, Willamette Valley Center Institute and Research Center, Eugene, OR

ADCETRIS is not approved for the treatment of any non-lymphoma malignancy.

For more information about the meeting, visit the ASCO annual meeting website at


ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

2 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs